For the Inventor, By the Inventor

Enter assignee name

Cheongju, South Korea

Medytox Inc.

USPTO Granted Patents = 21

% Expired Patents = 4.8

EPO Patents = 10

Trademarks = 5

Forward Citations = 125

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Gi Hyeok Yang (17 out of 17 patents)

Hyun Ho Jung (17 out of 29 patents)

Chang Hoon Rhee (14 out of 14 patents)

4. Hack Woo Kim (7 out of 7 patents)

5. Hyun Jee Kim (6 out of 6 patents)

6. Hee Dong Woo (4 out of 5 patents)

7. Junho Lee (3 out of 113 patents)

8. Sujin Cho (2 out of 2 patents)

9. Sung Bum Kim (2 out of 2 patents)

10. Seung Hwan Baek (2 out of 2 patents)

11. Hyun Uk Jeong (2 out of 4 patents)

12. Gi Hyuck Ryu (1 out of 1 patent)

13. Hyung Pyo Hong (1 out of 1 patent)

14. Jung Hyun Song (1 out of 1 patent)

15. Joon Chan Kong (1 out of 1 patent)

21 patents: Sort by Forward Citations

1. 12419836 - Extracellular vesicles derived from recombinant microorganism including polynucleotide encoding target protein and use thereof (2025-09-23),

2. 12377137 - Long lasting effect of new botulinum toxin formulations (2025-08-05),

3. 12274739 - Pharmaceutical liquid composition of botulinum toxin with improved stability (2025-04-14),

4. 11957741 - Long lasting effect of new botulinum toxin formulations (2024-04-16),

5. 11801276 - Microorganism having ability to degrade ethanol and acetaldehyde, and composition and kit each including the same (2023-10-31),

6. 11596673 - Long lasting effect of new botulinum toxin formulations (2023-03-07),

7. 11590212 - Long lasting effect of new botulinum toxin formulations (2023-02-28),

8. 11517576 - Methods and compositions of bile acids and salts for reduction of fat (2022-12-06),

9. 11331598 - Method of isolating botulinum toxin from botulinum toxin-containing solution (2022-05-17),

10. 11198859 - Recombinant polynucleotide coding for polypeptide comprising reporter moiety, substrate moiety and destabilizing moiety, host cell comprising same and use of same (2021-12-14),

11. 11161872 - Methods for preparing bile acids (2021-11-02),

12. 10729700 - Methods and compositions of bile acids and salts for reduction of fat (2020-08-04),

13. 10293034 - Pharmaceutical liquid composition of botulinum toxin with improved stability and method of use (2019-05-21),

14. 10143728 - Long lasting effect of new botulinum toxin formulations (2018-12-04),

15. 10105387 - Temperature sensitive adhesion prevention composition and use thereof (2018-10-23),

Company Overview

Medytox Inc. is a biopharmaceutical company based in Cheongju, South Korea, specializing in the development and manufacture of innovative therapeutic solutions. The company focuses on botulinum toxin products and other biologics, aiming to address various medical and aesthetic needs. Medytox is committed to advancing its research in neurology and dermatology, leveraging cutting-edge technology to enhance patient outcomes and expand its global presence in the biopharmaceutical market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

21 Patents

#8 in Cheongju

#611 in South Korea

#29,961 in the World

Cheongju, South Korea

Medytox Inc.

Forward Citations = 125

40 inventors:

Gi Hyeok Yang (17 out of 17 patents)

Hyun Ho Jung (17 out of 29 patents)

Chang Hoon Rhee (14 out of 14 patents)

4. Hack Woo Kim (7 out of 7 patents)

5. Hyun Jee Kim (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medytox Inc.. Retrieved from https://idiyas.com/company/medytox

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…